| Title |
Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, January 2019
|
| DOI | 10.1186/s40425-018-0475-y |
| Pubmed ID | |
| Authors |
Abdul Rafeh Naqash, Danielle M. File, Carolyn M. Ziemer, Young E. Whang, Paula Landman, Paul B. Googe, Frances A. Collichio |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 5 | 63% |
| Italy | 1 | 13% |
| Japan | 1 | 13% |
| Spain | 1 | 13% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 50% |
| Practitioners (doctors, other healthcare professionals) | 2 | 25% |
| Scientists | 1 | 13% |
| Science communicators (journalists, bloggers, editors) | 1 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 38 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 5 | 13% |
| Student > Doctoral Student | 4 | 11% |
| Researcher | 3 | 8% |
| Student > Master | 3 | 8% |
| Student > Ph. D. Student | 2 | 5% |
| Other | 6 | 16% |
| Unknown | 15 | 39% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 14 | 37% |
| Psychology | 2 | 5% |
| Biochemistry, Genetics and Molecular Biology | 1 | 3% |
| Agricultural and Biological Sciences | 1 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 3% |
| Other | 3 | 8% |
| Unknown | 16 | 42% |
Attention Score in Context
This research output has an Altmetric Attention Score of 13. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 February 2019.
All research outputs
#2,722,898
of 25,385,509 outputs
Outputs from Journal for Immunotherapy of Cancer
#744
of 3,424 outputs
Outputs of similar age
#61,547
of 446,389 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#21
of 81 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. Compared to these this one has done well and is in the 89th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,424 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.4. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 446,389 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 86% of its contemporaries.
We're also able to compare this research output to 81 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.